Abstract:Clustered regularly interspaced short palindromic repeat (CRISPR)-based genome editing (GED) technologies have unlocked exciting possibilities for understanding genes and improving medical treatments. On the other hand, Artificial intelligence (AI) helps genome editing achieve more precision, efficiency, and affordability in tackling various diseases, like Sickle cell anemia or Thalassemia. AI models have been in use for designing guide RNAs (gRNAs) for CRISPR-Cas systems. Tools like DeepCRISPR, CRISTA, and DeepHF have the capability to predict optimal guide RNAs (gRNAs) for a specified target sequence. These predictions take into account multiple factors, including genomic context, Cas protein type, desired mutation type, on-target/off-target scores, potential off-target sites, and the potential impacts of genome editing on gene function and cell phenotype. These models aid in optimizing different genome editing technologies, such as base, prime, and epigenome editing, which are advanced techniques to introduce precise and programmable changes to DNA sequences without relying on the homology-directed repair pathway or donor DNA templates. Furthermore, AI, in collaboration with genome editing and precision medicine, enables personalized treatments based on genetic profiles. AI analyzes patients’ genomic data to identify mutations, variations, and biomarkers associated with different diseases like Cancer, Diabetes, Alzheimer’s, etc. However, several challenges persist, including high costs, off-target editing, suitable delivery methods for CRISPR cargoes, improving editing efficiency, and ensuring safety in clinical applications. This review explores AI’s contribution to improving CRISPR-based genome editing technologies and addresses existing challenges. It also discusses potential areas for future research in AI-driven CRISPR-based genome editing technologies. The integration of AI and genome editing opens up new possibilities for genetics, biomedicine, and healthcare, with significant implications for human health.

Integration of Artificial Intelligence and CRISPR/Cas9 System for Vaccine Design

Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics

Advancing genome editing with artificial intelligence: opportunities, challenges, and future directions

Expanding Genome Editing Scopes with Artificial Intelligence.

Vaccine design and development: Exploring the interface with computational biology and AI

Design of highly functional genome editors by modeling the universe of CRISPR-Cas sequences

aiCRISPRL: An Artificial Intelligence Platform for Stem Cell and Organoid Simulation with Extensive Gene Editing Capabilities

An overview: CRISPR/Cas-based gene editing for viral vaccine development

The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy

Computationally guided high-throughput engineering of an anti-CRISPR protein for precise genome editing in human cells

CRISPR/Cas Technology: The Unique Synthetic Biology Genome-Editing Tool Shifting the Paradigm in Viral Diagnostics, Defense, and Therapeutics

Health Research in the Era of Artificial Intelligence: Advances in Gene-Editing Study

Vaccine development using artificial intelligence and machine learning: A review

CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool

The CRISPR/Cas system: Gene Editing by bacterial defense

Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer

Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy

The CRISPR System and Cancer Immunotherapy Biomarkers.

Therapeutic applications of CRISPR/Cas9 system in gene therapy

CRISPR-Cas9 Genome Editing for Cancer Immunotherapy: Opportunities and Challenges.